FDA Inspection 1252246 — Zhejiang Starry Pharmaceutical Co. Ltd.
The FDA completed an inspection of Zhejiang Starry Pharmaceutical Co. Ltd. on September 6, 2024 in Taizhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 6, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)